Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Weijing Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6549-9605; OpenAlex author ID A5019734570. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 12

  1. Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): a phase II study (NIRA-PANC). Last author DOI 10.1093/oncolo/oyag225↗
  2. Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients. Co-author DOI 10.3390/cells12182266↗
  3. Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy. Last author DOI 10.18053/jctres.07.202102.008↗
  4. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice. Co-author DOI 10.1053/j.gastro.2019.11.279↗
  5. Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer. Co-author DOI 10.3390/jcm9103283↗
  6. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2019.1588↗
  7. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.31628↗
  8. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response. Co-author DOI 10.21037/jgo.2017.01.23↗
  9. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. First author DOI 10.1186/s13045-015-0141-5↗
  10. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally a… Co-author DOI 10.1007/s00280-013-2147-4↗
  11. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-13-1320↗
  12. Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study. Co-author DOI 10.1097/coc.0b013e3181d26b01↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anup Kasi · 5 shared papers, 2020–2026 · strength 0.71
  2. Steven A. Soper · 2 shared papers, 2023–2026 · strength 0.38
  3. Anwaar Saeed · 2 shared papers, 2020–2026 · strength 0.34
  4. Jessica Allen · 2 shared papers, 2020–2021 · strength 0.25
  5. Prasad R. Dandawate · 2 shared papers, 2020–2021 · strength 0.22
  6. Shrikant Anant · 2 shared papers, 2020–2021 · strength 0.22
  7. Nathan Bahary · 3 shared papers, 2011–2018 · strength 0.15
  8. Ian M. Freed · 1 shared paper, 2023 · strength 0.15
  9. Stefan H. Bossmann · 1 shared paper, 2021 · strength 0.14
  10. Herbert J. Zeh · 2 shared papers, 2017–2018 · strength 0.13
  11. Gaurav Goel · 1 shared paper, 2015 · strength 0.11
  12. Neesha C. Dhani · 1 shared paper, 2019 · strength 0.08
  13. Myung Ah Lee · 1 shared paper, 2019 · strength 0.08
  14. Eileen Mary O'Reilly · 1 shared paper, 2019 · strength 0.08
  15. Do‐Youn Oh · 1 shared paper, 2019 · strength 0.08
  16. Aram F. Hezel · 1 shared paper, 2019 · strength 0.08
  17. George Albert Fisher · 1 shared paper, 2019 · strength 0.08
  18. Daniel John Renouf · 1 shared paper, 2019 · strength 0.08
  19. Philip A. Philip · 1 shared paper, 2019 · strength 0.08
  20. Domenico Coppola · 1 shared paper, 2020 · strength 0.08
  21. Chandrayee Ghosh · 1 shared paper, 2020 · strength 0.08
  22. Dharmalingam Subramaniam · 1 shared paper, 2020 · strength 0.08
  23. Subhash Padhyé · 1 shared paper, 2020 · strength 0.08
  24. Mokenge Peter Malafa · 1 shared paper, 2020 · strength 0.08
  25. Animesh Dhar · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.